Advances in the treatment of chronic inflammatory demyelinating neuropathies in 2010

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an uncommon disease of the peripheral nerves. The diagnosis is based mainly on clinical presentation, cerebrospinal fluid (CSF) examination, and electrodiagnostic studies. Treatment of CIDP has at least two components: supportive care and specific therapy including primarily steroids, intravenous immunoglobulins (IVIg), and plasmapheresis (PE). This review summarizes progress in the treatment of CIDP published during the last year.

Diagnostic utility of somatosensory evoked potentials in chronic polyradiculopathy without electrodiagnostic signs of peripheral demyelination

“…Several CIDP criteria, based on clinical presentation and NCS evidence of peripheral demyelination, have been proposed . CIDP is defined as a sensorimotor symmetric non–length‐dependent neuropathy with a progressive course over 2 months, unexplained by known causes of neuropathy, with NCS findings indicative of demyelination on motor NCS.…”

“…The diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) is crucial, because effective immunotherapies are available . The diagnosis is based on clinical, biological, and electrodiagnostic features .…”

“…The diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) is crucial, because effective immunotherapies are available . The diagnosis is based on clinical, biological, and electrodiagnostic features . However, electrodiagnostic (EDx) criteria rely on motor conduction velocities assessed by nerve conduction studies (NCS) and may fail to show demyelination, either because of secondary axonal degeneration or when motor nerve conduction is normal in pure sensory forms of polyradiculopathy.…”